@prefix this: <http://bio2rdf.org/drugbank:DB08811_nanopub.RAK__VaRHcr0QWFc64wFbnb8JOPrVg2SKaRbu2FnWB7qQ> .
@prefix sub: <http://bio2rdf.org/drugbank:DB08811_nanopub.RAK__VaRHcr0QWFc64wFbnb8JOPrVg2SKaRbu2FnWB7qQ#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix v: <http://bio2rdf.org/bio2rdf_vocabulary:> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:publicationInfo ;
    a np:Nanopublication .
}
sub:assertion {
   d:DB08811 v:identifier "DB08811" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB08811" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB08811> ;
    dv:drugbank-id "DB08811" ;
    dv:x-atc <http://bio2rdf.org/atc:N05BA23> ;
    dv:x-cas <http://bio2rdf.org/cas:22345-47-7> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D01254> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA165958428> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Tofisopam> ;
    dct:description "Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such compounds. Although Tofisopam is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. The D-enantiomer (dextofisopam) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome."@en ;
    dct:identifier "drugbank:DB08811" ;
    dct:title "Tofisopam"@en ;
    a dv:Drug ;
    rdfs:label "Tofisopam [drugbank:DB08811]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB08811> .
}
sub:provenance {
   sub:assertion prov:wasDerivedFrom <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  dr:bio2rdf.dataset.drugbank.R3 dcat:distribution <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime ;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> .
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime ;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> .
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> prov:wasAttributedTo <http://drugbank.ca> .
}
sub:publicationInfo {
   sub:signature.MCwCFF0e37g5HQYY npx:hasPublicKey "MIIBtzCCASwGByqGSM44BAEwggEfAoGBAP1/U4EddRIpUt9KnC7s5Of2EbdSPO9EAMMeP4C2USZpRV1AIlH7WT2NWPq/xfW6MPbLm1Vs14E7gB00b/JmYLdrmVClpJ+f6AR7ECLCT7up1/63xhv4O1fnxqimFQ8E+4P208UewwI1VBNaFpEy9nXzrith1yrv8iIDGZ3RSAHHAhUAl2BQjxUjC8yykrmCouuEC/BYHPUCgYEA9+GghdabPd7LvKtcNrhXuXmUr7v6OuqC+VdMCz0HgmdRWVeOutRZT+ZxBxCBgLRJFnEj6EwoFhO3zwkyjMim4TwWeotUfI0o4KOuHiuzpnWRbqN/C/ohNWLx+2J6ASQ7zKTxvqhRkImog9/hWuWfBpKLZl6Ae1UlZAFMO/7PSSoDgYQAAoGAETGrDm8R3KfndKRj7ttr3jVhhstI6/2Ey0ER9F5kdx7Hrd6eolq7yWzPzf2H754tdZxICzxYcdawBbL2ZUzFjWwXTNUQC3+e6evKPJyNELubnZcA+8TxIIwicBnw3Ku6mSeI8SUVr5SBV1VeJoSu/ahldv562IdBR8IagmzuT3Y=" ;
    npx:hasSignature "MCwCFF0e37g5HQYYRfm5Y18WyN1wyoZ5AhRg8wQHnXTOL4gbj2sI+X2pcrNDig==" ;
    npx:signedBy instance: .
  this: dct:created "2018-03-30T11:11:06.886+02:00"^^xsd:dateTime ;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/> ;
    npx:hasSignatureElement sub:signature.MCwCFF0e37g5HQYY ;
    prov:wasGeneratedBy process: .
  instance: prov:specializationOf codebase: ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475" ;
    prov:used version: ;
    prov:wasAssociatedWith instance: ;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  version: dct:isVersionOf codebase: ;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349" ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}